Oracle Press Release

Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection

Oracle® Remote Data Capture 4.5.3 Delivers Value to Customers by Providing a Scalable, Best-in-Class Electronic Data Capture System

Redwood Shores, CA – January 21, 2009

News Facts

Organizations spanning the life sciences industry – including biopharmaceutical companies, contract research organizations (CROs) and pharmaceutical manufacturers – are increasingly turning to Oracle® Remote Data Capture (RDC) 4.5.3 to conduct trials more efficiently and effectively.
Boehringer Ingelheim, Bristol-Myers Squibb, ICON, LEO Pharma, PPD and Quintiles Transnational are among a rapidly growing group of customers using Oracle RDC 4.5.3 to help increase efficiency in clinical trials data collection, improve data quality and enhance decision making.
Oracle RDC 4.5.3, the latest release of Oracle’s best-in-class electronic data capture (EDC) offering, is completely Web-based – with zero client footprint for the HTML data entry window – which enables improved global access and performance.
This enables life sciences organizations to conduct global clinical studies more cost effectively using paper, electronic data capture, or hybrid methods.
The Oracle EDC application helps meet the needs of trial sponsors as well as investigative site personnel by providing a simplified user interface and eliminating site software installation. This helps to increase staff efficiency by allowing investigators to quickly locate patient visits and case report forms (CRFs).
Oracle RDC 4.5.3 is integrated with Oracle Clinical, the industry’s leading clinical data management system, and is an integral component of Oracle’s extensive suite of clinical trial management applications.

Supporting Quotes

“As one of the largest users of Oracle Remote Data Capture 4.5.3, PPD is providing clients with the robustness and flexibility this system offers. We have realized greater efficiencies since implementing Oracle RDC 4.5.3, including reduced study timelines, real-time decision making and ease of use for investigator sites,” said Susan Atkinson, Senior Vice President of Biostatistics and Data Management, PPD.
“As a global clinical research organization, we manage clinical trials for the world’s top 20 pharmaceutical organizations and leading biotechnology companies. Oracle Remote Data Capture 4.5.3 helps us to accelerate the capture of subject data and offers a robust system of edit checks to ensure the data accuracy and integrity essential to effectively managing global mega trials,” said Tom O’Leary, Global Head of Data Management, ICON Clinical Research.
“Quintiles Transnational is committed to enhancing clinical trial efficiency for its biotech and pharmaceutical clients worldwide. We looked to Oracle Remote Data Capture to help us rationalize and accelerate the clinical trial process through automated data collection, and more rapid data processing and reporting,” said Nicolas Schaltenbrand, Senior Director, Global Data Management, Quintiles Transnational.
“Life sciences organizations increasingly require software applications that will help them automate and effectively manage the clinical phase from study setup through submission. Oracle’s comprehensive suite of applications for clinical development provides an integrated system for managing large volumes of patient data, as well as sophisticated tracking, analysis and reporting capabilities. Today, hundreds of life sciences organizations are harnessing the power of Oracle’s clinical solutions to accelerate insights for better health,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences Global Business Unit.

Supporting Resources

About Oracle

Oracle (NASDAQ: ORCL) is the world's largest enterprise software company. For more information about Oracle, please visit our Web site at


Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owners.

Contact Info

Kevin Ruane

Mary Tobin
O’Keeffe & Company